Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spe
-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses --DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Mu...
Source: pharmiweb.com